HSV-targeted immunotherapy
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for HSV-targeted immunotherapy, covering 2025-06-12 to 2025-09-08. Get the full timeline:
Most recent: Clinical Trial Update: A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes [Phase 1, Phase 2]